ETF Holdings Breakdown of CPRX

Stock Name	Catalyst Pharmaceuticals Inc
Ticker	CPRX(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US14888U1016
LEI	5299004O0R5XXLA5H544

CPRX institutional holdings

The following institutional investment holdings of CPRX have been identified

Date ETF ISIN/Name Num Shares Book value
2025-10-17 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 72,613 USD 1,492,197

2025-10-17 IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc)) 149,086 USD 3,063,717

2025-10-17 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 78,501 USD 1,613,196

2025-10-17 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 4,362 USD 89,639

Total = 304,562 USD 6,258,749
Book value of shares is calculated on the adjusted close price of each day (row).

Date	ETF ISIN/Name	Num Shares	Book value
2025-10-17	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	72,613	USD 1,492,197
2025-10-17	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	149,086	USD 3,063,717
2025-10-17	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	78,501	USD 1,613,196
2025-10-17	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	4,362	USD 89,639
Total =	304,562	USD 6,258,749

News associated with CPRX

Mutual of America Capital Management LLC Sells 657 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX): Mutual of America Capital Management LLC lessened its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 3.9% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 16,327 shares of the biopharmaceutical company’s stock after selling 657 shares during the quarter. Mutual of America […] - 2025-08-13 05:45:09
Maryland State Retirement & Pension System Sells 4,969 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX): Maryland State Retirement & Pension System lowered its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 13.2% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 32,706 shares of the biopharmaceutical company’s stock after selling 4,969 shares during the period. Maryland State Retirement & […] - 2025-08-13 05:06:50
Wall Street Zen Downgrades Catalyst Pharmaceuticals (NASDAQ:CPRX) to Hold: Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Free Report) was downgraded by Wall Street Zen from a “strong-buy” rating to a “hold” rating in a research report issued on Saturday. Separately, Cantor Fitzgerald raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, June 5th. One investment analyst has rated the stock […] - 2025-08-11 05:44:53
Zurcher Kantonalbank Zurich Cantonalbank Has $774,000 Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX): Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 11.3% in the first quarter, Holdings Channel.com reports. The firm owned 31,897 shares of the biopharmaceutical company’s stock after acquiring an additional 3,244 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Catalyst Pharmaceuticals were worth […] - 2025-08-06 06:08:49
Federated Hermes Inc. Decreases Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX): Federated Hermes Inc. decreased its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 57.3% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 74,484 shares of the biopharmaceutical company’s stock after selling 99,906 shares during the quarter. Federated Hermes Inc. owned […] - 2025-08-06 05:12:59
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives $32.83 Consensus Target Price from Brokerages: Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Free Report) have been given an average recommendation of “Buy” by the eight analysts that are presently covering the stock, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average […] - 2025-07-25 05:48:50
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Holdings Lifted by New York State Common Retirement Fund: New York State Common Retirement Fund grew its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 155.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 92,001 shares of the biopharmaceutical company’s stock after purchasing an additional 55,968 shares during […] - 2025-07-24 04:40:46
Alps Advisors Inc. Reduces Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX): Alps Advisors Inc. lessened its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 3.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,476 shares of the biopharmaceutical company’s stock after selling 633 shares during the […] - 2025-07-15 06:26:34
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Oregon Public Employees Retirement Fund: Oregon Public Employees Retirement Fund lessened its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 2.7% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 25,639 shares of the biopharmaceutical company’s stock after selling 705 shares during the period. Oregon Public Employees Retirement Fund’s holdings in […] - 2025-07-08 05:24:52
Wealth Enhancement Advisory Services LLC Grows Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX): Wealth Enhancement Advisory Services LLC increased its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 65.0% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 35,334 shares of the biopharmaceutical company’s stock after acquiring an additional 13,915 shares during the quarter. Wealth […] - 2025-07-03 04:26:50
Oppenheimer & Co. Inc. Lowers Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX): Oppenheimer & Co. Inc. decreased its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 5.5% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 98,746 shares of the biopharmaceutical company’s stock after selling 5,741 shares during the period. Oppenheimer & […] - 2025-06-27 05:48:55
XML Financial LLC Sells 20,000 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX): XML Financial LLC cut its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 66.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,000 shares of the biopharmaceutical company’s stock after selling 20,000 shares during the […] - 2025-06-25 05:35:06
Sound Income Strategies LLC Takes Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX): Sound Income Strategies LLC acquired a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) in the 1st quarter, HoldingsChannel.com reports. The firm acquired 2,654 shares of the biopharmaceutical company’s stock, valued at approximately $64,000. Other hedge funds and other institutional investors have also recently made changes to their positions in the […] - 2025-06-17 05:26:52
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock Holdings Increased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC: UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 11.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 263,905 shares of the biopharmaceutical company’s […] - 2025-06-03 05:13:09
Mackenzie Financial Corp Grows Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX): Mackenzie Financial Corp boosted its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 132.9% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 34,531 shares of the biopharmaceutical company’s stock after buying an additional 19,705 shares during the quarter. Mackenzie Financial Corp’s holdings in Catalyst Pharmaceuticals were worth $721,000 at […] - 2025-06-02 05:49:04
Tidal Investments LLC Reduces Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX): Tidal Investments LLC trimmed its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 4.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 38,141 shares of the biopharmaceutical company’s stock after selling 1,905 shares during the period. Tidal Investments […] - 2025-05-27 05:22:56
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Raises Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX): MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 3.4% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 68,252 shares of the biopharmaceutical company’s stock after buying an additional 2,252 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in Catalyst Pharmaceuticals […] - 2025-05-25 07:56:51
BNP Paribas Financial Markets Has $2.67 Million Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX): BNP Paribas Financial Markets cut its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 16.7% during the 4th quarter, Holdings Channel reports. The firm owned 127,679 shares of the biopharmaceutical company’s stock after selling 25,571 shares during the quarter. BNP Paribas Financial Markets’ holdings in Catalyst Pharmaceuticals were worth $2,665,000 as […] - 2025-05-16 05:24:51
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock Holdings Lowered by The Manufacturers Life Insurance Company: The Manufacturers Life Insurance Company reduced its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 2.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,366 shares of the biopharmaceutical company’s stock after selling 1,444 shares during the quarter. The Manufacturers […] - 2025-05-13 05:26:56
Envestnet Asset Management Inc. Acquires 39,836 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX): Envestnet Asset Management Inc. lifted its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 162.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 64,395 shares of the biopharmaceutical company’s stock after purchasing an additional 39,836 shares during the quarter. Envestnet […] - 2025-04-30 04:27:02
Barclays PLC Sells 4,035 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX): Barclays PLC lessened its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 1.6% in the 4th quarter, Holdings Channel reports. The firm owned 244,423 shares of the biopharmaceutical company’s stock after selling 4,035 shares during the period. Barclays PLC’s holdings in Catalyst Pharmaceuticals were worth $5,101,000 at the end of the most recent […] - 2025-04-27 05:54:51
Raymond James Financial Inc. Invests $6.89 Million in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX): Raymond James Financial Inc. acquired a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 329,980 shares of the biopharmaceutical company’s stock, valued at approximately $6,887,000. Several other hedge funds have […] - 2025-04-24 04:41:07
Summit Investment Advisors Inc. Boosts Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX): Summit Investment Advisors Inc. grew its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 5.2% in the fourth quarter, Holdings Channel.com reports. The firm owned 11,696 shares of the biopharmaceutical company’s stock after buying an additional 580 shares during the period. Summit Investment Advisors Inc.’s holdings in Catalyst Pharmaceuticals were worth […] - 2025-04-22 05:47:00
Cerity Partners LLC Has $548,000 Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX): Cerity Partners LLC decreased its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 7.8% during the 4th quarter, HoldingsChannel.com reports. The firm owned 26,482 shares of the biopharmaceutical company’s stock after selling 2,251 shares during the period. Cerity Partners LLC’s holdings in Catalyst Pharmaceuticals were worth $548,000 as of its most […] - 2025-04-22 04:50:54
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Bought by Russell Investments Group Ltd.: Russell Investments Group Ltd. increased its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 1.4% during the fourth quarter, Holdings Channel reports. The fund owned 176,259 shares of the biopharmaceutical company’s stock after purchasing an additional 2,471 shares during the quarter. Russell Investments Group Ltd.’s holdings in Catalyst Pharmaceuticals were worth $3,679,000 as […] - 2025-04-16 05:06:59
Analysts Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Price Target at $32.29: Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Free Report) have earned a consensus rating of “Buy” from the eight ratings firms that are covering the firm, Marketbeat.com reports. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target […] - 2025-04-14 03:01:01
Corebridge Financial Inc. Cuts Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX): Corebridge Financial Inc. lessened its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 7.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 59,539 shares of the biopharmaceutical company’s stock after selling 4,627 shares during the period. Corebridge Financial Inc.’s holdings in […] - 2025-04-04 05:10:55
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Holdings Boosted by Commonwealth Equity Services LLC: Commonwealth Equity Services LLC raised its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 133.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 39,331 shares of the biopharmaceutical company’s stock after acquiring an additional 22,455 shares during the period. […] - 2025-04-03 04:20:49
KLP Kapitalforvaltning AS Invests $772,000 in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX): KLP Kapitalforvaltning AS bought a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 37,000 shares of the biopharmaceutical company’s stock, valued at approximately $772,000. Several other hedge funds and other institutional […] - 2025-04-01 05:17:01
Cibc World Markets Corp Acquires New Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX): Cibc World Markets Corp bought a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) during the 4th quarter, HoldingsChannel.com reports. The fund bought 10,463 shares of the biopharmaceutical company’s stock, valued at approximately $218,000. A number of other hedge funds have also bought and sold shares of the stock. Steward Partners […] - 2025-03-27 06:54:57

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.